metastas
repres
main
caus
death
melanoma
patient
despit
current
optim
target
therapi
immun
checkpoint
inhibitor
treatment
metastat
melanoma
unsatisfactori
poor
prognosi
advanc
melanoma
urgent
need
identifi
new
biomark
differenti
melanoma
cell
normal
melanocyt
stratifi
patient
accord
risk
identifi
subgroup
patient
requir
close
followup
aggress
therapi
furthermor
melanoma
progress
associ
dysregul
cell
adhes
molecul
review
literatur
discuss
import
role
express
carcinoembryon
antigen
cell
adhes
molecul
develop
melanoma
thu
novel
insight
may
lead
promis
strategi
melanoma
treatment
monitor
melanoma
patient
assess
respons
immunotherapi
complet
standard
immunohistochem
panel
use
melanoma
examin
metastas
repres
main
caus
death
melanoma
patient
metastat
melanoma
treatment
unsatisfactori
even
current
optim
target
therapi
brafoncogen
inhibitor
immun
checkpoint
inhibitor
anticytotox
tlymphocyteassoci
antigen
antiprogram
protein
program
death
protein
date
lactat
dehydrogenas
ldh
serum
biomark
use
clinic
practic
melanoma
howev
sensit
specif
ldh
predict
metastat
recurr
low
consid
rel
unsatisfactori
potenti
ldh
biomark
poor
prognosi
advanc
melanoma
numer
attempt
group
other
made
identifi
new
biomark
stratifi
patient
accord
risk
thu
identifi
subgroup
patient
requir
closer
followup
aggress
therapi
new
blood
biomark
panel
includ
ceacam
test
order
complet
laboratori
imag
recommend
monitor
patient
melanoma
markel
et
al
report
higher
level
serum
melanoma
patient
compar
healthi
donor
melanoma
immunogen
tumor
malign
melanocyt
present
high
rate
dna
mutat
express
tumor
antigen
elicit
multipl
immun
respons
dysregul
cell
adhes
molecul
associ
diseas
progress
melanoma
thu
novel
insight
carcinoembryon
antigen
cell
adhes
molecul
may
lead
promis
strategi
melanoma
treatment
also
refer
ccam
biliari
glycoprotein
bgp
complex
glycoprotein
link
cell
membran
carboxytermin
transmembran
anchor
belong
carcinoembryon
antigen
cea
famili
immunoglobulin
superfamili
far
six
ceacam
glycoprotein
describ
character
sever
domain
ndomain
membran
igvrel
domain
onemultipl
domain
ndomain
may
bind
homophil
heterophil
cea
ceacam
thu
act
cellcel
adhes
molecul
encod
chromosom
express
sever
type
cell
epitheli
cell
apic
pole
epitheli
cell
gastrointestin
tract
esophag
gland
duoden
brunner
gland
intestin
colon
superfici
epitheli
cell
epitheli
cell
gall
bladder
bile
duct
pancreat
duct
mammari
duct
epitheli
cell
endometrium
renal
tubular
epithelium
prostat
gland
extravil
intermedi
trophoblast
etc
endotheli
cell
b
lymphocyt
natur
killer
cell
myeloid
cell
express
mediat
intercellular
protein
interact
intracellular
signal
inflamm
microbi
viral
infect
angiogenesi
cancer
progress
metastasi
role
inflamm
complex
due
altern
splice
gener
variou
isoform
human
eight
transmembran
isoform
present
includ
lymphocyt
splice
variant
long
cytoplasm
tail
associ
inhibitori
function
ex
vivo
vivo
inhibit
tcell
receptor
complex
moreov
splice
variant
also
enhanc
fibrinogen
adhes
via
fc
receptor
integrin
involv
modul
innat
adapt
immun
respons
via
express
b
lymphocyt
natur
killer
cell
myeloid
cell
role
cell
inhibit
direct
cell
receptor
crosslink
bind
neisseria
opac
associ
protein
inhibit
nk
cell
independ
major
histocompat
complex
class
depend
cytosol
tail
regul
angiogenesi
target
sever
process
chemotaxi
endotheli
cell
prolifer
tube
format
biolog
function
addit
vascular
endotheli
growth
factor
vegf
effect
demonstr
upregul
induc
vegf
well
vitro
obstruct
vegfinduc
tube
format
sever
tissu
overexpress
endotheli
cell
normal
patholog
nontumor
highli
prolifer
tissu
normal
andor
pregnant
endometrium
granul
tissu
tumor
tissu
solid
human
tumor
also
interven
insulin
action
regul
increas
clearanc
insulin
stimul
receptormedi
insulin
endocytosi
degrad
use
variou
pathogen
adher
eukaryot
cell
instanc
haemophilu
influenza
moraxella
catarrhali
escherichia
coli
variou
speci
neisseria
salmonella
use
ndomain
microbi
receptor
human
granulocyt
epitheli
cell
sever
virus
coronavirus
mous
hepat
viru
type
sever
acut
respiratori
syndrom
coronaviru
sarscov
use
solubl
form
enter
host
cell
furthermor
also
involv
apoptot
control
two
mechan
cleavag
isoform
intraand
extracellularli
caspas
activ
high
express
level
detect
melanoma
adenocarcinoma
small
cell
lung
cancer
lower
level
detect
colon
prostat
breast
cancer
melanoma
homophil
interact
inhibit
natur
killer
nk
cell
activ
effector
function
cytotox
interferon
gamma
ifn
releas
tumorinfiltr
lymphocyt
til
upregul
induc
ifn
melanoma
cell
surviv
tilmedi
attack
render
cell
even
resist
ceacam
express
melanoma
often
note
invad
part
tumor
associ
increas
melanoma
cell
invas
migrat
ceacam
also
interfer
cellmatrix
adhes
enhanc
cell
motil
modul
ncadherin
intercellular
adhes
glycoprotein
epithelialmesenchym
transit
marker
recent
studi
evidenc
correl
express
melanoma
cell
line
melanoma
tissu
microphthalmiaassoci
transcript
factor
mitf
mitf
modul
prolifer
invas
melanoma
mechan
involv
mitf
correl
melanoma
may
involv
sex
determin
region
sri
relat
hmgbox
transcript
factor
involv
chondrogenesi
sex
determin
embryo
function
normal
melanocyt
upregul
melanin
synthesi
melanocyt
cell
ultraviolet
b
shortwav
ray
uvb
exposur
increas
mitf
dopachrom
tautomeras
tyrosinerel
protein
tyrosinas
express
increas
express
melanoma
inhibit
tumor
cell
prolifer
bind
directli
via
mitf
whether
directli
indirectli
regul
express
still
matter
debat
differ
author
obtain
oppos
result
possibl
due
differ
type
cell
studi
colon
epithelium
versu
melanoma
cell
line
differ
role
fulfil
colon
carcinoma
tumor
growth
suppressor
melanoma
tumor
diseas
marker
aggress
promot
also
mitf
bind
promot
mbox
motif
thu
directli
stimul
express
moreov
induc
overexpress
turn
induc
catenin
express
mechan
involv
acquir
tumor
aggress
increas
invas
melanoma
cell
upregul
similar
progress
upregul
nevi
metastat
melanoma
present
surfac
normal
melanocyt
lack
data
regard
express
melanocyt
nevi
gambichl
et
al
perform
immunohistochem
studi
analyz
express
benign
malign
cutan
tumor
normal
peritumor
skin
benign
nevi
case
dysplast
nevi
case
thin
superfici
spread
melanoma
case
thick
superfici
spread
melanoma
case
result
report
percentag
posit
stain
melanocyt
studi
lesion
median
express
benign
nevi
dysplast
nevi
thin
superfici
spread
melanoma
breslow
tumor
thick
mm
thick
superfici
spread
melanoma
breslow
tumor
thick
mm
compar
benign
nevi
median
express
significantli
increas
thin
thick
superfici
spread
melanoma
significantli
increas
dysplast
nevi
compar
dysplast
nevi
median
express
significantli
increas
thick
superfici
spread
melanoma
peritumor
skin
melanocyt
immunohistochem
reactiv
cea
famili
express
immunohistochem
assess
differ
subtyp
melanocyt
nevi
junction
acquir
nevi
compound
acquir
nevi
intraderm
acquir
nevi
compound
congenit
nevi
intraderm
congenit
nevi
blue
nevi
author
use
panel
monoclon
polyclon
antibodi
recogn
differ
epitop
cea
cearel
molecul
includ
none
antibodi
use
studi
recogn
result
studi
reveal
increas
express
cea
glycoprotein
famili
variou
type
analyz
nevi
except
blue
nevi
neg
stain
also
observ
normal
melanocyt
carcinoembryon
antigen
famili
express
melanocyt
nevi
similar
pattern
acquir
congenit
one
present
blue
nevi
repres
neural
crest
melanocyt
fail
reach
epidermi
embryolog
migrat
vitro
investig
evidenc
invas
migrat
melanocyt
cell
express
enhanc
author
studi
melanocyt
cell
line
invas
capac
cell
transfect
transfect
cell
show
higher
invas
motil
properti
compar
untransfect
cell
gamblich
studi
case
superfici
spread
melanoma
ssm
use
differ
antibodi
reveal
membran
cytoplasm
stain
tumor
cell
express
significantli
higher
ssm
compar
benign
nevi
author
notic
progress
increas
benign
nevi
dysplast
nevi
thin
ssm
thick
ssm
author
highlight
signific
posit
correl
express
breslow
tumor
thick
clark
level
superfici
spread
melanoma
thi
et
al
evalu
case
primari
melanoma
express
stain
intens
invas
part
lesion
case
posit
melanoma
metastas
case
neg
melanoma
metastas
vessel
stain
identifi
patient
associ
express
microvessel
prognosi
activ
human
tumorinfiltr
lymphocyt
deriv
patient
melanoma
cell
express
inhibitori
effect
follow
homophil
interact
author
conclud
express
melanoma
cell
independ
factor
regardless
ulcer
statu
mitot
rate
tumor
thick
risk
metastasi
predict
valu
superior
tumor
thick
patient
ident
paramet
american
joint
committe
cancer
ajcc
classif
statu
provid
accur
predict
estim
studi
essenti
interplay
melanoma
tumorinfiltr
lymphocyt
markel
et
al
coincub
melanoma
cell
tumorinfiltr
cell
vitro
result
experi
show
progress
increas
express
melanoma
cell
resist
attack
infiltr
lymphocyt
increas
express
depend
presenc
interferon
gamma
ortenberg
et
al
show
metastat
cutan
melanoma
lesion
express
express
increas
tumor
progress
khatib
et
al
first
evalu
express
case
primari
uveal
melanoma
metastas
frequent
affect
organ
liver
identifi
primari
uveal
melanoma
liver
metastas
similar
express
cutan
melanoma
correspond
metastas
presenc
primari
tumor
correl
develop
metastas
surviv
vivo
studi
show
overexpress
promot
xenograft
tumorigen
melanoma
directli
inhibit
activ
nk
lymphocyt
result
increas
express
melanoma
cell
surviv
vitro
immun
attack
inhibit
new
immun
cell
vitro
studi
evidenc
anoth
possibl
mechan
respons
data
express
melanocyt
cell
neg
melanocyt
cell
line
melanoma
cell
neg
melanoma
cell
line
increas
invas
migratori
properti
melanocyt
melanoma
cell
interact
integrin
cell
migrat
also
modul
interact
protein
filamin
reduc
migratori
potenti
author
evidenc
addit
stimul
migrat
could
also
inhibit
cell
migrat
small
seri
patient
zippel
et
al
notic
borderlin
signific
increas
membran
stain
primari
lesion
lymph
node
distant
metastas
current
practic
immunohistochem
stain
melana
human
melanoma
black
use
identifi
melanoma
cell
clinic
neg
sentinel
lymph
node
improv
rate
detect
compar
hematoxylin
eosin
stain
alon
immunohistochem
marker
sensit
specif
detect
melanoma
cell
primari
melanoma
sentinel
lymph
node
distant
metastas
studi
thi
et
al
express
cell
adhes
molecul
analyz
compar
express
standard
marker
melana
case
primari
melanoma
case
sentinel
lymph
node
case
distant
metastas
case
benign
nevi
author
compar
sensit
marker
melana
describ
result
similar
studi
report
sensit
primari
melanoma
correspond
metastat
lymph
node
author
also
compar
two
differ
antibodi
highlight
superior
sensit
monoclon
antibodi
commerci
regard
specif
immunohistochem
marker
melanoma
cell
relev
observ
describ
highli
specif
melanoma
cell
melana
context
benign
nevu
cell
inclus
capsul
sentinel
lymph
node
could
lead
fals
posit
diagnosi
melanoma
metastas
antibodi
higher
specif
sensit
melanoma
cell
lymphat
hematogen
metastas
ad
standard
panel
antibodi
studi
ortenberg
et
al
found
posit
stain
metastat
melanoma
lymphocyt
surround
metastas
wide
distribut
metastat
melanoma
qualifi
target
therapi
alon
combin
new
immun
checkpoint
inhibitor
anti
anti
tumorspecif
sometim
associ
sever
immunolog
side
effect
vitro
vivo
studi
melanoma
xenograft
show
antibodi
built
target
extracellular
portion
block
ndomain
murin
monoclon
antibodi
human
influenc
prolifer
rate
facilit
melanoma
cell
elimin
cell
agonist
effect
regard
safeti
concern
antibodi
effect
normal
epitheli
cell
express
effect
activ
cell
normal
posit
cell
autoimmun
event
directli
affect
posit
cell
induc
nonspecif
activ
cell
thought
concomit
block
immunotherapi
adopt
cellular
transfer
act
might
improv
clinic
respons
novel
specif
monoclon
antibodi
melanoma
immunotherapi
base
function
block
avail
ccam
biotherapeut
agenu
inc
phase
trial
go
center
usa
center
israel
primari
outcom
measur
avail
januari
block
may
revers
inhibitori
action
nk
activ
cell
enhanc
antitumor
effect
endogen
immun
system
normal
identifi
serum
healthi
individu
low
level
melanoma
patient
level
correl
amount
tumor
cell
secret
patient
melanoma
also
show
high
percentag
posit
lymphocyt
peripher
blood
secret
influenc
total
serum
level
metastat
melanoma
level
solubl
significantli
correl
ldh
level
current
ldh
serolog
biomark
includ
ajcc
stage
system
import
independ
prognost
factor
advanc
stage
iv
melanoma
specif
sensit
egbert
collabor
found
calciumbind
protein
b
evalu
superior
ldh
identif
earli
distant
metastasi
level
marker
correl
poor
outcom
shorter
diseasefre
overal
surviv
sivan
et
al
monitor
ldh
serum
level
patient
region
metastat
diseas
prior
autolog
vaccin
patient
evid
diseas
show
significantli
higher
level
ceacam
compar
patient
evid
diseas
healthi
volunt
reflect
diseas
burden
kluger
group
also
show
plasma
elev
patient
metastat
melanoma
compar
healthi
control
earli
stage
diseas
serum
level
correl
diseas
activ
overal
surviv
rate
level
solubl
invers
correl
time
death
melanoma
patient
activ
diseas
major
patient
normal
ldh
level
valu
facilit
precis
prognost
predict
review
articl
highlight
import
role
express
develop
melanoma
promot
melanoma
progress
enhanc
migrat
invas
melanoma
cell
impair
antitumor
immun
respons
nk
cell
mechan
interact
melanoma
biolog
incomplet
elucid
vitro
studi
reveal
relat
express
melanoma
cell
behavior
increas
express
melanoma
cell
line
amplifi
invad
capac
cell
downregul
express
melanoma
cell
decreas
expans
abil
cell
hand
express
modul
melanoma
cell
escap
immunolog
attack
melanoma
cell
tumorinfiltr
lymphocyt
coincub
vitro
surviv
melanoma
cell
increas
express
depend
constant
presenc
interferon
gamma
posit
lymphocyt
abund
patient
melanoma
melanoma
cell
possibl
transfer
attack
lymphocyt
affect
effici
immun
reaction
patient
receiv
immunotherapi
melanoma
use
adopt
cell
transfer
tumorinfiltr
lymphocyt
downregul
major
histocompat
complex
mhc
class
often
describ
reduc
surfac
express
mhc
class
molecul
seen
melanoma
cell
overexpress
express
correl
poor
prognosi
melanoma
patient
sinc
melanoma
immunogen
diseas
constitut
attract
target
immunotherapi
correl
serum
melanoma
progress
surviv
support
standard
biomark
monitor
melanoma
patient
assess
respons
immunotherapi
due
high
specif
sensit
antibodi
melanoma
metastas
could
enhanc
standard
immunohistochem
panel
use
melanoma
examin
review
literatur
brought
focu
key
molecul
one
latest
hallmark
cancer
involv
main
mechan
respons
increas
invas
melanocyt
report
immunoexpress
scarc
literatur
due
promis
potenti
assess
diagnosi
target
treatment
consid
investig
warrant
advanc
current
knowledg
anticytotox
tlymphocyteassoci
antigen
antiprogram
protein
program
death
protein
ldh
lactat
dehydrogenas
cea
carcinoembryon
antigen
vegf
vascular
endotheli
growth
factor
ifn
n
e
r
f
e
r
ng
uvb
ultraviolet
b
shortwav
ray
sex
determin
region
ybox
ajcc
american
joint
committe
cancer
human
melanoma
black
calciumbind
protein
b
mhc
major
histocompat
complex
